Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Molecular tumour board: Where do we stand? What’s next?

Personalised oncogenomics: Is a precision approach necessary for every cancer or is there a therapy-driven bottleneck?


29 Sep 2019


Molecular tumour board: Where do we stand? What’s next?


Cancer Biology;  Pathology/Molecular Biology;  Rare Cancers

Tumour Site

Ovarian Cancer;  Endometrial Cancer


David Huntsman


D. Huntsman

Author affiliations

  • Department Pathology And Laboratory Medicine, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.